MX2017013350A - Comprimido de ribociclib. - Google Patents

Comprimido de ribociclib.

Info

Publication number
MX2017013350A
MX2017013350A MX2017013350A MX2017013350A MX2017013350A MX 2017013350 A MX2017013350 A MX 2017013350A MX 2017013350 A MX2017013350 A MX 2017013350A MX 2017013350 A MX2017013350 A MX 2017013350A MX 2017013350 A MX2017013350 A MX 2017013350A
Authority
MX
Mexico
Prior art keywords
ribociclib
tablet
directed
present disclosure
coating
Prior art date
Application number
MX2017013350A
Other languages
English (en)
Spanish (es)
Inventor
Grandeury Arnaud
Gururajan Bindhumadhavan
Costa Rui
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017013350(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2017013350A publication Critical patent/MX2017013350A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2017013350A 2015-04-16 2016-04-14 Comprimido de ribociclib. MX2017013350A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562148240P 2015-04-16 2015-04-16
PCT/IB2016/052136 WO2016166703A1 (en) 2015-04-16 2016-04-14 Ribociclib tablet

Publications (1)

Publication Number Publication Date
MX2017013350A true MX2017013350A (es) 2018-01-25

Family

ID=55806565

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013350A MX2017013350A (es) 2015-04-16 2016-04-14 Comprimido de ribociclib.

Country Status (29)

Country Link
US (6) US10799506B2 (OSRAM)
EP (3) EP4197530B1 (OSRAM)
JP (1) JP2018514523A (OSRAM)
KR (2) KR102750931B1 (OSRAM)
CN (2) CN107530292B (OSRAM)
AR (1) AR104257A1 (OSRAM)
AU (5) AU2016248017A1 (OSRAM)
BR (1) BR112017021283A2 (OSRAM)
CA (1) CA2982425C (OSRAM)
CL (1) CL2017002593A1 (OSRAM)
CO (1) CO2017010510A2 (OSRAM)
DK (1) DK3283058T3 (OSRAM)
EA (1) EA201792290A1 (OSRAM)
EC (1) ECSP17075052A (OSRAM)
ES (1) ES2938261T3 (OSRAM)
FI (1) FI3283058T3 (OSRAM)
HR (1) HRP20230053T1 (OSRAM)
HU (1) HUE061213T2 (OSRAM)
IL (1) IL254818A0 (OSRAM)
MX (1) MX2017013350A (OSRAM)
PE (1) PE20180035A1 (OSRAM)
PH (1) PH12017501820A1 (OSRAM)
PL (1) PL3283058T3 (OSRAM)
PT (1) PT3283058T (OSRAM)
SG (1) SG11201708084PA (OSRAM)
SI (1) SI3283058T1 (OSRAM)
TN (1) TN2017000422A1 (OSRAM)
TW (1) TW201642864A (OSRAM)
WO (1) WO2016166703A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3283058T3 (fi) * 2015-04-16 2023-03-01 Novartis Ag Ribosiklibitabletti
CA3048036A1 (en) 2018-07-02 2020-01-02 Apotex Inc Novel crystalline form of ribociclib succinate
CN114667147B (zh) 2019-08-26 2024-09-06 阿尔维纳斯运营股份有限公司 用四氢萘衍生物作为雌激素受体降解剂的治疗乳腺癌的方法
JP7681599B2 (ja) 2019-12-16 2025-05-22 ルネラ・バイオテック・インコーポレーテッド 選択的cdk4/6阻害剤のがん治療薬
KR20220113986A (ko) 2019-12-16 2022-08-17 루넬라 바이오테크 인코포레이티드 선택적 cdk 4/6 억제제 암 치료제
WO2022029798A1 (en) * 2020-08-03 2022-02-10 Natco Pharma Limited Pharmaceutical compositions comprising ribociclib
US20230355578A1 (en) * 2020-09-29 2023-11-09 Laboratorios Silanes S.A. De C.V. Pharmaceutical combinations of statins and fibrates for the treatment and prevention of hyperlipidemias and cardiovascular disease
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
CN117396208A (zh) 2021-07-16 2024-01-12 达纳-法伯癌症研究所公司 细胞周期蛋白依赖性激酶4/6(cdk4/6)和ikzf2(helios)的小分子降解剂及其使用方法
TWI848533B (zh) 2022-01-25 2024-07-11 瑞士商諾華公司 瑞博西尼藥物組成物
EP4580631A1 (en) 2022-08-31 2025-07-09 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders
WO2024115680A1 (en) 2022-12-01 2024-06-06 Krka, D.D., Novo Mesto Ribociclib salts and formulations thereof
AU2024244511A1 (en) 2023-03-27 2025-09-25 Novartis Ag Method of treating early breast cancer with ribociclib in combination with an aromatase inhibitor
WO2025219830A1 (en) 2024-04-15 2025-10-23 Novartis Ag Pharmaceutical compositions of ribociclib

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5428812A (en) * 1977-08-09 1979-03-03 Yoshitomi Pharmaceut Ind Ltd Preparation of coated tablet
GB9414045D0 (en) 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
JP3672314B2 (ja) * 1994-07-12 2005-07-20 バーウィンド・ファーマスーティカル・サーヴィスィーズ・インコーポレーテッド 防湿性フィルム被覆材組成物、方法および被覆成形物
US6448323B1 (en) * 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
US8685980B2 (en) 2008-08-22 2014-04-01 Novartis Ag Pyrrolopyrimidine compounds and their uses
US20110070301A1 (en) * 2009-09-24 2011-03-24 Luber Joseph R Orally transformable tablets
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
SG192666A1 (en) * 2011-02-11 2013-09-30 Wista Lab Ltd Phenothiazine diaminium salts and their use
JP6226978B2 (ja) * 2012-07-13 2017-11-08 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体モジュレーター(sarm)によりアンドロゲン受容体(ar)陽性乳癌を処置する方法
EP2742940B1 (en) * 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
EP2934515B1 (en) * 2012-12-20 2018-04-04 Novartis AG A pharmaceutical combination comprising binimetinib
UA118846C2 (uk) * 2013-03-21 2019-03-25 Новартіс Аг Комбінована терапія
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
FI3283058T3 (fi) * 2015-04-16 2023-03-01 Novartis Ag Ribosiklibitabletti
CN109953966A (zh) * 2017-12-26 2019-07-02 天津耀辰实业发展有限公司 一种含有瑞博西尼的药物组合物及其制备方法
JP7347388B2 (ja) 2020-09-25 2023-09-20 信越化学工業株式会社 紫外線硬化型有機変性シリコーン組成物および硬化物

Also Published As

Publication number Publication date
SI3283058T1 (sl) 2023-03-31
US20250090531A1 (en) 2025-03-20
CN115554257A (zh) 2023-01-03
PT3283058T (pt) 2023-02-03
KR20170137101A (ko) 2017-12-12
CA2982425A1 (en) 2016-10-20
US20250127785A1 (en) 2025-04-24
US20250134893A1 (en) 2025-05-01
CL2017002593A1 (es) 2018-05-18
AU2019201929B2 (en) 2020-07-09
PL3283058T3 (pl) 2023-03-20
JP2018514523A (ja) 2018-06-07
TN2017000422A1 (en) 2019-01-16
EP4197530B1 (en) 2025-11-12
EP4197530A1 (en) 2023-06-21
US20230104792A1 (en) 2023-04-06
EP3283058A1 (en) 2018-02-21
AU2022215155A1 (en) 2022-09-01
EP4620458A3 (en) 2025-10-22
CO2017010510A2 (es) 2018-03-20
ES2938261T3 (es) 2023-04-05
AU2016248017A1 (en) 2017-10-19
BR112017021283A2 (pt) 2018-06-26
PE20180035A1 (es) 2018-01-09
CN107530292B (zh) 2022-11-01
PH12017501820A1 (en) 2018-04-23
EP3283058B1 (en) 2022-11-16
HUE061213T2 (hu) 2023-05-28
US20200390771A1 (en) 2020-12-17
DK3283058T3 (da) 2023-02-13
US10799506B2 (en) 2020-10-13
KR102750931B1 (ko) 2025-01-09
KR20250009572A (ko) 2025-01-17
AU2022215155B2 (en) 2024-08-01
ECSP17075052A (es) 2018-02-28
CA2982425C (en) 2023-10-31
FI3283058T3 (fi) 2023-03-01
AU2019201929A1 (en) 2019-04-11
CN107530292A (zh) 2018-01-02
AU2020250190A1 (en) 2020-11-05
EP4620458A2 (en) 2025-09-24
HRP20230053T1 (hr) 2023-03-03
WO2016166703A1 (en) 2016-10-20
AR104257A1 (es) 2017-07-05
TW201642864A (zh) 2016-12-16
SG11201708084PA (en) 2017-10-30
AU2024227794A1 (en) 2024-11-21
US12419894B2 (en) 2025-09-23
US20180071292A1 (en) 2018-03-15
EA201792290A1 (ru) 2018-02-28
IL254818A0 (en) 2017-12-31
US12064434B2 (en) 2024-08-20

Similar Documents

Publication Publication Date Title
PH12017501820A1 (en) Ribociclib tablet
EP3246328A4 (en) Quinazoline heterocyclic compound as egfr kinase inhibitor, and preparation and application thereof
WO2017075629A3 (en) Wee 1 kinase inhibitors and methods of making and using the same
EP3278803A4 (en) Solid pharmaceutical dosage form of parp inhibitor, and application of solid pharmaceutical dosage form of parp inhibitor
EP3038539A4 (en) Heart anchor positioning devices, methods, and systems for treatment of congestive heart failure and other conditions
EP3362930A4 (en) SYSTEMS, COMPOSITIONS, AND METHODS FOR DISCOVERING MSI AND NEOEPPITOPES THAT PROVIDE SENSITIVITY TO IMMUNE CONTROL POINTS
EP3290420A4 (en) Pyrimidine pyrrole compound, preparation method therefor, pharmaceutical composition, and uses thereof
IN2015DN01286A (OSRAM)
EP3130592A4 (en) Analogues of 4h-pyrazolo[1,5- ]benzimidazole compound as parp inhibitors
IL280641A (en) Converted benzimidazoles as PAD4 inhibitors
WO2014204881A8 (en) Delayed release cysteamine bead formulation
EP3124486A4 (en) Substituted nitrogen-containing heterocyclic derivatives, pharmaceutical compositions comprising the same and applications of antitumor thereof
EP3630113A4 (en) PHARMACEUTICAL COMPOSITION INCLUDING A PDE9 INHIBITOR
EP3256672A4 (en) Access-control fixture lock
EP3078671A4 (en) Gemcitabine derivative, composition containing the derivative and pharmaceutical use of the derivative
MX372834B (es) PREPARACION FARMACEUTICA COMBINADA QUE COMPRENDE EL BLOQUEANTE DEL RECEPTOR DE LA ANGIOTENSINA II Y EL INHIBIDOR DE LA HMG-CoA REDUCTASA.
EP3325564A4 (en) AQUEOUS COATING COMPOSITION
GB2543709A (en) Pharmaceutical agent
CY1120192T1 (el) Ενωσεις για την ενισχυση της γνωστικης λειτουργιας
EP3303319B8 (en) Derivatives of 1,2,3-triazolyl cyclohexan-1-ol and its use
EP3024427A4 (en) Derivatives of 2,2,6-trimethylcyclohexane-carboxylate
JO3298B1 (ar) مشتقات جليكوبيرانوسيل-مستبدل و اندول-يوريا و استعمالاتهم كمثبطات sglt
MX2016008225A (es) Composiciones para cuidado oral y metodos.
EP3253202A4 (en) Acid herbicide-containing compositions, precursors, derivatives, and methods
HK40054295A (en) Substituted benzimidazoles as pad4 inhibitors